How to Prepare for a Pre-IND Meeting with FDA

For early-stage biotech companies developing novel therapeutics, the Pre-IND meeting with FDA represents one of the most consequential milestones on the path to clinical development. A well-prepared Pre-IND meeting can clarify regulatory expectations, de-risk your nonclinical program, and save months of misdirected effort. A poorly prepared one can leave you with vague guidance and lingering uncertainty. This guide walks you through the process from start to finish, so you can approach your first FDA interaction with confidence.

What Is a Pre-IND Meeting?

A Pre-IND meeting is a formal interaction between a drug sponsor and the U.S. Food and Drug Administration that occurs before the sponsor submits an Investigational New Drug (IND) application. The purpose is to get FDA feedback on your proposed development plan, including nonclinical strategy, chemistry/manufacturing/controls (CMC), and early clinical trial design.

Pre-IND meetings are classified as Type B meetings under FDA's guidance for formal meetings between sponsors and the agency. Type B meetings are the most common category for substantive development discussions. FDA will grant or deny the meeting request within 21 calendar days and schedule the meeting to occur within 60 calendar days of the original request.

Why the Pre-IND Meeting Matters

• Regulatory alignment early: You learn whether FDA agrees with your proposed nonclinical package before you commit significant capital to IND-enabling studies.
• Species and model selection: FDA can weigh in on whether your proposed animal models are appropriate for your modality, which is particularly important for gene therapies, RNA therapeutics, and other advanced modalities where standard toxicology approaches may not apply.
• Clinical hold prevention: Misalignment on nonclinical requirements is one of the most common reasons for clinical holds. A Pre-IND meeting reduces that risk.
• Investor confidence: Having documented FDA feedback strengthens your narrative with investors and partners.

When to Request a Pre-IND Meeting

Timing is critical. You should plan to request your Pre-IND meeting typically 3 to 4 months before you need FDA's feedback to inform your IND-enabling study designs. Here is a general timeline:

• Month 0: Submit meeting request to the appropriate FDA review division.
• By Day 21: FDA grants or denies the meeting request. If granted, the meeting date is provided (typically within 60 days of the original request).
• At least 30 days before the meeting: You submit the briefing document (meeting package).
• Meeting day or written response: FDA provides feedback, either in a face-to-face meeting, teleconference, videoconference, or written response only.

Triggers That Signal You Are Ready

• You have a defined lead candidate and target indication.
• Your nonclinical strategy is outlined but not yet locked (you want FDA input before committing).
• You have preliminary pharmacology and/or proof-of-concept data.
• Your CMC plan is at least directionally defined, even if the process is not final.
• You can articulate specific questions for the agency.

If you are still in discovery or lack a clear development candidate, the meeting is premature. FDA expects sponsors to bring substantive proposals to react to, not open-ended requests for guidance.

The Meeting Request Package

The meeting request is a formal submission, typically sent to the relevant review division within CDER or CBER. Gene therapies, cell therapies, and vaccines are reviewed by CBER, while most therapeutic biologics (monoclonal antibodies, fusion proteins, ADCs) are reviewed by CDER. The request should include:

• Product name and description: Brief overview of the therapeutic, mechanism of action, and intended indication.
• Meeting type: Specify Type B Pre-IND.
• Objectives: Clearly state what you want to accomplish.
• Proposed agenda and questions: List the specific questions you intend to ask (these will be refined in the briefing document).
• Proposed meeting format: Face-to-face, teleconference, videoconference, or written response only.

A concise, well-organized meeting request signals professionalism and helps FDA assign the right reviewers.

Writing the Briefing Document

The briefing document is the most important deliverable in the entire Pre-IND process. FDA reviewers will use it to formulate their responses, and in many cases, the written response is based almost entirely on the briefing document without a live meeting.

Recommended Structure

• Executive Summary: One to two pages covering the product, indication, development stage, and purpose of the meeting.
• Product Overview: Mechanism of action, modality-specific considerations (e.g., vector design for gene therapies, delivery system for RNA therapeutics), and target patient population.
• Nonclinical Program Summary: Completed studies (pharmacology, PK, preliminary toxicology) and proposed IND-enabling studies (GLP toxicology, biodistribution, genotoxicity if applicable).
• CMC Summary: Manufacturing process overview, analytical strategy, and current stage of process development.
• Proposed Clinical Plan: Phase 1 design, dose rationale, patient population, endpoints, and safety monitoring plan.
• Questions for FDA: Numbered, specific, and answerable.

Writing Effective Questions

This is where many sponsors fall short. Effective Pre-IND questions share several characteristics:

• Specific, not open-ended: "Do you agree that a 28-day GLP toxicology study in cynomolgus monkeys with a 4-week recovery period is adequate to support the proposed Phase 1 dosing regimen?" is far more useful than "What nonclinical studies do we need?"
• Propose your approach first: FDA responds best when reacting to a specific proposal rather than generating plans from scratch.
• Prioritize ruthlessly: Aim for 5 to 10 well-crafted questions, noting that sub-questions count toward the total. Keeping the list focused ensures FDA reviewers can provide substantive responses to each.
• Cover the high-risk areas: Focus questions on areas of genuine uncertainty, such as species relevance, biomarker strategy, or novel manufacturing considerations.

What to Expect from FDA's Response

FDA responses to Pre-IND meetings generally take one of two forms:

Written Response Only

In many cases, particularly for straightforward programs, FDA will provide a written response to your questions without scheduling a live meeting. This is not a negative outcome. Written responses are documented, specific, and can be referenced in your IND submission.

Live Meeting (Teleconference or In-Person)

If a live meeting is scheduled, it typically runs 60 minutes. FDA will have pre-read your briefing document and typically provides preliminary written responses before the meeting. The live discussion allows for follow-up questions and clarification.

Key expectations:

• FDA will not design your program for you. They react to what you propose.
• Responses may include partial agreement with caveats or recommendations.
• FDA advice at the Pre-IND stage is generally non-binding, but documented feedback carries significant weight during IND review.
• You will receive official meeting minutes within 30 calendar days of the meeting.

Common Pitfalls to Avoid

Submitting Too Early

If your program is not mature enough to present a specific proposal, you will get generic guidance that does not meaningfully advance your development plan.

Vague or Overly Broad Questions

Questions like "What does FDA recommend for our nonclinical program?" force the agency into a consulting role they are not designed to fill. Propose your plan and ask whether they agree.

Underestimating the Briefing Document

Some sponsors treat the briefing document as a formality. It is the opposite. FDA reviewers across multiple disciplines will base their feedback on this document. Invest the time to make it thorough, well-organized, and scientifically rigorous.

Ignoring Modality-Specific Guidance

FDA has published specific guidance documents for gene therapies, RNA-based therapeutics, and other advanced modalities. Your briefing document and questions should demonstrate awareness of the relevant guidance and address modality-specific considerations (e.g., vector shedding, immunogenicity, biodistribution).

Failing to Align Internally Before Engaging FDA

Before submitting your meeting request, ensure your internal team (or fractional leadership and advisors) is aligned on the proposed development strategy. FDA interactions go poorly when the sponsor's own team is not unified on the plan.

Building Your Pre-IND Strategy Team

Most seed-to-Series A biotech companies do not have a full regulatory affairs department. Building the right team for Pre-IND preparation typically involves:

• Regulatory affairs expertise: Someone who understands FDA meeting mechanics, formatting requirements, and how to navigate the review division.
• Nonclinical leadership: A senior scientist or fractional Head of Preclinical who can design and defend the proposed nonclinical package.
• CMC input: Even at an early stage, FDA expects a directional CMC strategy.
• Clinical perspective: A clinical advisor who can articulate the proposed Phase 1 design and dose rationale.

For early-stage companies, fractional leadership models can provide this expertise without the overhead of full-time hires across every function. The key is ensuring that whoever leads the Pre-IND preparation has direct experience with FDA interactions and understands the nuances of your specific modality.

Timeline and Budget Planning

A realistic timeline for Pre-IND meeting preparation, from decision to submit through receipt of FDA feedback, is typically 4 to 6 months:

Budget considerations vary widely, but sponsors should anticipate costs associated with regulatory consulting or fractional leadership support, scientific writing, and internal team time for review and alignment.

After the Pre-IND Meeting

Once you receive FDA's feedback, the real work begins:

• Document everything: Ensure you have official meeting minutes and reconcile them with your own notes.
• Update your development plan: Incorporate FDA's feedback into your nonclinical, CMC, and clinical plans.
• Communicate with stakeholders: Share relevant outcomes with your board, investors, and development partners.
• Begin IND-enabling work: With FDA alignment in hand, you can move forward with greater confidence in your study designs.